Resources
About Us
Home Report
Store
Middle East & Africa Molecular Diagnostics Market
Middle East & Africa Molecular Diagnostics Market by Offering (Reagents, Kits, Systems, Software) Test Type (Lab, PoC) Technology (PCR, ISH, INAAT, Sequencing, Microarray) Application (Influenza, HPV, Oncology, Gene Testing) End User - Forecast to 2031
Report ID:MRHC - 1041108 Pages: 200 Feb-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 72 HoursThe Middle East & Africa Molecular Diagnostics Market was valued at $0.77 billion in 2023. This market is expected to reach $1.16 billion by 2031, from an estimated $0.81 billion in 2024, at a CAGR of 5.4% during the forecast period 2024-2031.
Middle East & Africa Molecular Diagnostics Market Size & Forecast
Molecular diagnostics help identify specific genetic material within human, viral, and bacterial genomes. These tests are becoming increasingly prevalent across various fields, including infectious diseases, oncology, and clinical genetics. As advancements in molecular diagnostics persist, they will further enhance the accuracy and efficiency of diagnosis, ultimately becoming integral components of personalized patient interventions and therapeutic approaches.
The growth of the Middle East & Africa molecular diagnostics market is driven by factors such as the rising prevalence of communicable and non-communicable diseases, technological advancements in molecular diagnostics, increasing investments and funding aimed at enhancing healthcare systems in the Middle East & Africa, and the rising healthcare expenditure in the region. However, inconsistencies in medical device regulations across the Middle East & Africa and the high costs of molecular diagnostic tests restrain the market’s growth.
Emerging medical and wellness tourism in the UAE and a growing focus on companion diagnostics are expected to create market growth opportunities. However, the shortage of skilled professionals poses a significant challenge to the growth of this market.
Initiatives Aimed at Enhancing Healthcare Systems Driving Market’s Growth
The governments of Middle Eastern countries are taking initiatives to enhance and advance their healthcare infrastructure. For instance, Saudi Arabia has implemented a comprehensive set of reforms as part of its Vision 2030 strategy, aimed at improving various sectors including healthcare. Within the healthcare sector, the Saudi Vision 2030 outlines plans to increase the number of public hospitals, clinical laboratories, and upgraded facilities throughout the kingdom.
Additionally, major companies in the region are prioritizing partnerships and intensifying their expansion efforts in the Middle East & Africa. For instance
- In January 2022, GC Labs (South Korea) proposed a “smart lab” concept that provides an automated test system to improve the speed and efficiency of tests. The increased demand for genetics and infectious diseases tests in the region has made GC Labs plan further expansion in the Middle East.
- In December 2021, AstraZeneca Gulf FZ LLC (UAE) partnered with G42 Healthcare (UAE) to boost the research and diagnostics in molecular diagnostics technology in the UAE. In June 2021, G42 Healthcare also signed a Memorandum of Understanding (MoU) with Seegene, Inc. (South Korea) to offer fully equipped mobile diagnostics and testing laboratories across the Middle East and North Africa (MENA) region. The partnership was aimed at providing the Seegene Mobile Station, a laboratory-on-wheels facility to provide optimized molecular diagnosis and tests across MENA, including the UAE, Algeria, Morocco, Tunisia, Libya, Egypt, Sudan, Palestine, Jordan, Syria, Iraq, Iran, Pakistan, Lebanon, Kuwait, Qatar, Oman, Saudi Arabia, Bahrain, and Yemen.
Funding and Investments to Improve Accessibility to Healthcare Services Driving Market’s Growth
Healthcare expenditure encompasses all financial investments necessary for healthcare systems to operate effectively and deliver high-quality care to patients. The increase in healthcare expenditure can facilitate regular health interventions, such as annual medical checkups and preventive screenings, which are likely to enhance the overall health status of a country. Despite the relatively low healthcare expenditure in the African region, various private and public organizations are actively investing in Africa to enhance basic healthcare infrastructure and combat diseases. For instance, in June 2022, the Bill & Melinda Gates Foundation (BMGF) announced a USD 140 million funding initiative over four years aimed at supporting new initiatives and research conducted by African institutions to combat malaria and neglected tropical diseases (NTDs). Similarly, in June 2020, New Frontier Capital Management (NCFM), a Japanese-owned investment firm, invested USD 300 million in the development of hospitals, medical infrastructure, medical systems, health tech, and health promotion in the Middle East & Africa region. Such investments are expected to drive the growth of the molecular diagnostics market in the years to come.
The rising healthcare expenditure indicates a growing emphasis on promoting health and preventing diseases, ultimately leading to an increased adoption of advanced medical technologies. This trend is accompanied by increased funding and initiatives for disease diagnosis and treatment, as well as the establishment of healthcare facilities and advanced infrastructure. These factors are increasing accessibility to advanced diagnostic methods for early diagnosis and treatment.
Click here to: Get Free Sample Pages of this Report
Key Findings of the Middle East & Africa Molecular Diagnostics Market Study:
The Reagents & Kits Segment is Expected to Account for the Largest Share of the Market in 2024
Among the offerings studied in this report, in 2024, the reagents & kits segment is expected to account for the largest share of the market. Molecular diagnostic kits are widely used by healthcare professionals in hospitals, clinics, and diagnostic laboratories to diagnose and manage various communicable & non-communicable diseases. Recurrent use of assays & kits in the detection of various diseases through molecular diagnostics, the proliferation of new products in the market, and technological advancements in molecular techniques contribute to the large market share of this segment. Partnerships, collaborations, and agreements among the players and other industry stakeholders are also positively impacting the market. In April 2023, Thermo Fisher Scientific, Inc. (U.S.) partnered with ALPCO Diagnostics (Czech Republic) to introduce 37 CE-IVD molecular assays to the market. One such assay is the TaqPath Menu| GeneProof PCR Kit, which can be used on a wide range of qPCR instruments. This kit facilitates the detection of various genetic diseases and pathogens, including STDs, respiratory infections, and bloodborne infections. These assays enable laboratories to conduct tests more rapidly and reduce the need for frequent instrument changes, enhancing efficiency. The tests are slated to be launched in regions such as the Middle East, Africa, Latin America, Asia, and select parts of Europe throughout 2024.
The Laboratory Tests Segment is Expected to Account for the Largest Share of the Market in 2024
Among the test types studied in this report, in 2024, the laboratory tests segment is expected to account for the largest share of the market. Laboratory tests have traditionally been conducted in hospitals and diagnostic centers. The laboratory testing approach for molecular diagnostics offers numerous advantages over other methods. It is characterized by higher accuracy and reliability compared to point-of-care testing, which contributes to its greater adoption in laboratory settings compared to PoC tests.
The Polymerase Chain Reaction (PCR) Segment is Expected to Account for the Largest Share of the Market in 2024
Among the technologies studied in this report, in 2024, the polymerase chain reaction (PCR) segment is expected to account for the largest share of the molecular diagnostics market in the Middle East & Africa. PCR enables the rapid amplification of a specific segment of DNA, making it a crucial technology that aids in disease diagnosis. Due to its effectiveness in detecting low-number targets and its cost-effectiveness compared to other technologies like sequencing, there is significant demand for PCR tests, further bolstering the segment's largest share. For instance, in February 2023, Dubai, UAE, hosted the "Medlab Middle East 2023" exhibition and conference, a 4-day event showcasing the latest products and technologies in laboratory management and diagnostics, including PCR. Such exhibitions and conferences play a crucial role in increasing awareness of advanced technologies and instrumentation.
The Infectious Disease Segment is Expected to Account for the Largest Share of the Market in 2024
Based on application, in 2024, the infectious disease segment is expected to account for the largest share of the molecular diagnostics market in the Middle East & Africa. The large market share of this segment can be attributed to the growing incidence of infectious diseases and increased funding for infectious disease diagnostic research activities. The availability of funding specifically allocated for infectious disease research contributes to the growth of this segment. For instance, in April 2021, the Jameel Fund for Infectious Disease Research and Innovation announced a research fund aimed at supporting collaborative research between King Abdulaziz University (KAU) in Saudi Arabia and Imperial College London in the U.K. Under this initiative, grants totaling USD 500,000 were provided, equally distributed between both universities to support research projects spanning three to six months in duration.
The Hospitals & Clinics Segment is Expected to Account for the Largest Share of the Market in 2024
Based on end user, in 2024, the hospitals & clinics segment is expected to account for the largest share of the molecular diagnostics market in the Middle East & Africa. The large market share of this segment can be attributed to various initiatives aimed at enhancing healthcare infrastructure in the Middle East & Africa, increased hospitalizations due to various diseases, the growing geriatric population, and the high incidence of infectious diseases. For instance, in January 2023, the Sub-Saharan African region announced plans to invest nearly USD 11 billion in developing new hospitals to bolster the healthcare infrastructure of the region.
Saudi Arabia: Largest Market in the Middle East & Africa
Saudi Arabia's significant market share can be attributed to factors such as the robust healthcare infrastructure in the country, the increasing prevalence of chronic and infectious diseases, and the rising spending on healthcare. According to the International Trade Administration (ITA), under the Vision 2030 initiative, the Saudi Arabian government plans to invest over USD 65 million in the development of healthcare infrastructure and to reorganize and privatize health services. In 2023, Saudi Arabia allocated nearly USD 50.4 billion for healthcare and social development, representing approximately 16.96% of the total budget for that year. This high healthcare spending underscores the country's strong focus on healthcare-related activities and services, including government procurements of pharmaceuticals, medical equipment, and supplies for the benefit of all public healthcare facilities.
Middle East & Africa Molecular Diagnostics Market: Competitive Analysis
The key players profiled in the Middle East & Africa molecular diagnostics market report are AstraGene LLC (U.A.E.), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Becton, Dickinson and Company (U.S.), Illumina, Inc. (U.S.), AstraZeneca Gulf FZ LLC (Dubai), QIAGEN N.V. (Netherlands), Danaher Corporation (U.S.), Abbott Laboratories (U.S), and Agilent Technologies, Inc. (U.S.).
The report includes a competitive landscape based on an extensive assessment of the market based on offering, test type, application, technology, and end user. The report also provides insights into the presence of major market players and the key growth strategies adopted by them over the past three to four years.
Middle East & Africa Molecular Diagnostics Market Report Summary:
|
Particular |
Details |
|
Page No |
~200 |
|
Format |
|
|
Forecast Period |
2024-2031 |
|
Base Year |
2023 |
|
CAGR |
5.4% |
|
Market Size (Value) |
$1.16 billion by 2031 |
|
Segments Covered |
By Offering
By Test Type
By Technology
By Application
By End User
|
|
Countries Covered |
Saudi Arabia, United Arab Emirates, Oman, Kuwait, Egypt, South Africa, and the Rest of the Middle East & Africa |
|
Key Companies |
AstraGene LLC (U.A.E.), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Becton, Dickinson and Company (U.S.), Illumina, Inc. (U.S.), AstraZeneca Gulf FZ LLC (Dubai), QIAGEN N.V. (Netherlands), Danaher Corporation (U.S.), Abbott Laboratories (U.S), Agilent Technologies, Inc. (U.S.) |
Key questions answered in the report:
This market study covers the market sizes & forecasts of the molecular diagnostics market in the Middle East & Africa based on offering, test type, technology, application, end user, and geography. This market study also provides the value analysis of various segments and subsegments of the Middle East & Africa molecular diagnostics market at country levels.
The Middle East & Africa molecular diagnostics market is projected to reach $1.16 billion by 2031, at a CAGR of 5.4% during the forecast period.
The kits & reagents segment is expected to account for the largest share of the market in 2024. Factors such as improved rate of disease diagnosis in the Middle East & Africa and recurrent use of kits and reagents in disease diagnostics contribute to the large market share of this segment.
The infectious diseases segment is expected to account for the largest share of the market in 2024. The growing incidence of infectious diseases, the rising funds for infectious disease diagnostic research activities, and the risk of the sudden emergence of a pandemic are factors contributing to the large market share of this segment.
The growth of the Middle East & Africa molecular diagnostics market is driven by factors such as the rising prevalence of communicable and non-communicable diseases, technological advancements in molecular diagnostics, increasing investments and funding aimed at enhancing healthcare systems in the Middle East & Africa, and the rising healthcare expenditure in the region.
Emerging medical and wellness tourism in the UAE and a growing focus on companion diagnostics are expected to create market growth opportunities.
The key players profiled in the Middle East & Africa molecular diagnostics market report are AstraGene LLC (U.A.E.), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Becton, Dickinson and Company (U.S.), Illumina, Inc. (U.S.), AstraZeneca Gulf FZ LLC (Dubai), QIAGEN N.V. (Netherlands), Danaher Corporation (U.S.), Abbott Laboratories (U.S), and Agilent Technologies, Inc. (U.S.).
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency and Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumption for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Drivers
4.2.1. Increasing Prevalence of Communicable & Non-communicable Diseases
4.2.2 Technological Advancements in Molecular Diagnostics
4.2.3. Increasing Investments and Fundings to Improve Healthcare Systems in Middle East & Africa
4.2.4. Rising Healthcare Expenditure
4.3. Restraints
4.3.1. Inconsistencies in Medical Device Regulations Across Middle East & African Countries
4.3.2. High Costs of Molecular Diagnostic Tests
4.4. Opportunities
4.4.1. Emerging Medical and Wellness Tourism in the UAE
4.4.2. Increasing Focus on Companion Diagnostics
4.5. Challenges
4.5.1. Shortage of Skilled Professionals
4.6. Industry & Technology Trends
4.7. Regulatory Scenario
4.8. Porter’s Five Forces Analysis
4.9. Adjacent/Related Market Analysis
5. Middle East & Africa Molecular Diagnostics Market Assessment—by Offering
5.1. Overview
5.2. Kits & Reagents
5.3. Instruments
5.4. Software & Services
6. Middle East & Africa Molecular Diagnostics Market Assessment—by Test Type
6.1. Overview
6.2. Laboratory Tests
6.3. Point-of-Care (POC) Tests
7. Middle East & Africa Molecular Diagnostics Market Assessment—by Technology
7.1. Overview
7.2. Polymerase Chain Reaction (PCR)
7.3. In Situ Hybridization (ISH)
7.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
7.5. Microarrays
7.6. Sequencing
7.7. Mass Spectrometry
7.8. Other Technologies
8. Middle East & Africa Molecular Diagnostics Market Assessment—by Application
8.1. Overview
8.2. Infectious Diseases
8.2.1. Respiratory Diseases
8.2.2. Hepatitis
8.2.3. HIV
8.2.4. Chlamydia Trachomatis/Neisseria Gonorrhoeae
8.2.5. Human Papillomavirus (HPV)
8.2.6. Healthcare-Associated Infections (HAIs)
8.2.7. Other Infectious Diseases
8.3. Oncology
8.3.1. Breast Cancer
8.3.2. Colorectal Cancer
8.3.3. Lung Cancer
8.3.4. Prostate Cancer
8.3.5. Lymphoma
8.3.6. Leukemia
8.3.7. Cervical Cancer
8.3.8. Other Cancer Types
8.4. Respiratory Diseases
8.5. Genetic Testing
8.6. Neurological Diseases
8.7. Cardiovascular Diseases
8.8. Other Applications
9. Middle East & Africa Molecular Diagnostics Market Assessment—by End User
9.1. Overview
9.2. Hospitals & Clinics
9.3. Diagnostic Laboratories
9.4. Academic & Research Institutes
9.5. Other End Users
10. Middle East & Africa Molecular Diagnostics Market Assessment—by Geography
10.1. Overview
10.2. Saudi Arabia
10.3. UAE
10.4. Oman
10.5. Kuwait
10.6. Egypt
10.7. South Africa
10.8. Rest of the Middle East & Africa
11. Competitive Analysis
11.1. Overview
11.2. Competitive Benchmarking
11.3. Competitive Dashboard
11.3.1 Market Leaders
11.3.2 Market Differentiators
11.3.3. Vanguards
11.3.4. Emerging Companies
11.4. Market Share Analysis/Market Ranking, by Key Players (2023)
12. Company Profiles (Company Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)
12.1. AstraGene LLC
12.2. F. Hoffmann-La Roche Ltd.
12.3. Thermo Fisher Scientific Inc.
12.4. Becton, Dickinson and Company (U.S.)
12.5. Illumina, Inc.
12.6. AstraZeneca Gulf FZ LLC
12.7. QIAGEN N.V.
12.8. Danaher Corporation
12.9. Abbott Laboratories
12.10. Agilent Technologies, Inc.
(Note: SWOT is Provided for the Top 5 Players)
13. Appendix
13.1. Available Customization
13.2. Related Reports
List of Tables
Table 1 Middle East & Africa Molecular Diagnostics Market, by Offering, 2022–2031 (USD Million)
Table 2 Middle East & Africa Molecular Diagnostics Kits & Reagents Market, by Country/Region, 2022–2031 (USD Million)
Table 3 Middle East & Africa Molecular Diagnostics Instruments Market, by Country/Region, 2022–2031 (USD Million)
Table 4 Middle East & Africa Molecular Diagnostics Software & Services Market, by Country/Region, 2022–2031 (USD Million)
Table 5 Middle East & Africa Molecular Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 6 Middle East & Africa Molecular Diagnostics Market for Laboratory Tests, by Country/Region, 2022–2031 (USD Million)
Table 7 Middle East & Africa Molecular Diagnostics Market for PoC Tests, by Country/Region, 2022–2031 (USD Million)
Table 8 Middle East & Africa Molecular Diagnostics Market, by Technology, 2022–2031 (USD Million)
Table 9 Middle East & Africa Molecular Diagnostics Market for Polymerase Chain Reaction (PCR), by Country/Region, 2022–2031 (USD Million)
Table 10 Middle East & Africa Molecular Diagnostics Market for In Situ Hybridization (ISH), by Country/Region, 2022–2031 (USD Million)
Table 11 Middle East & Africa Molecular Diagnostics Market for Isothermal Nucleic Acid Amplification Technology (INAAT), by Country/Region, 2022–2031 (USD Million)
Table 12 Middle East & Africa Molecular Diagnostics Market for Microarrays, by Country/Region, 2022–2031 (USD Million)
Table 13 Middle East & Africa Molecular Diagnostics Market for Mass Spectrometry, by Country/Region, 2022–2031 (USD Million)
Table 14 Middle East & Africa Molecular Diagnostics Market for Sequencing, by Country/Region, 2022–2031 (USD Million)
Table 15 Middle East & Africa Molecular Diagnostics Market for Other Technologies Market, by Country/Region, 2022–2031 (USD Million)
Table 16 Middle East & Africa Molecular Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 17 Middle East & Africa Molecular Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 18 Middle East & Africa Molecular Diagnostics Market for Infectious Diseases Market, by Country/Region, 2022–2031 (USD Million)
Table 19 Middle East & Africa Molecular Diagnostics Market for Respiratory Diseases, by Country/Region, 2022–2031 (USD Million)
Table 20 Middle East & Africa Molecular Diagnostics Market for Hepatitis Testing, by Country/Region, 2022–2031 (USD Million)
Table 21 Middle East & Africa Molecular Diagnostics Market for HIV Testing, by Country/Region, 2022–2031 (USD Million)
Table 22 Middle East & Africa Molecular Diagnostics Market for CT/NG Testing, by Country/Region, 2022–2031 (USD Million)
Table 23 Middle East & Africa Molecular Diagnostics Market for Human papillomavirus (HPV) Testing, by Country/Region, 2022–2031 (USD Million)
Table 24 Middle East & Africa Molecular Diagnostics Market for Healthcare-associated Infections (HAIs) Testing, by Country/Region, 2022–2031 (USD Million)
Table 25 Middle East & Africa Molecular Diagnostics Market for Other Infectious Diseases Testing, by Country/Region, 2022–2031 (USD Million)
Table 26 Middle East & Africa Molecular Diagnostics Market for Oncology, by Type, 2022–2031 (USD Million)
Table 27 Middle East & Africa Molecular Diagnostics Market for Oncology, by Country/Region, 2022–2031 (USD Million)
Table 28 Middle East & Africa Molecular Diagnostics Market for Breast Cancer, by Country/Region, 2022–2031 (USD Million)
Table 29 Middle East & Africa Molecular Diagnostics Market for Colorectal Cancer, by Country/Region, 2022–2031 (USD Million)
Table 30 Middle East & Africa Molecular Diagnostics Market for Lung Cancer, by Country/Region, 2022–2031 (USD Million)
Table 31 Middle East & Africa Molecular Diagnostics Market for Prostate Cancer, by Country/Region, 2022–2031 (USD Million)
Table 32 Middle East & Africa Molecular Diagnostics Market for Lymphoma, by Country/Region, 2022–2031 (USD Million)
Table 33 Middle East & Africa Molecular Diagnostics Market for Leukemia, by Country/Region, 2022–2031 (USD Million)
Table 34 Middle East & Africa Molecular Diagnostics Market for Cervical Cancer, by Country/Region, 2022–2031 (USD Million)
Table 35 Middle East & Africa Molecular Diagnostics Market for Other Cancer Types, by Country/Region, 2022–2031 (USD Million)
Table 36 Middle East & Africa Molecular Diagnostics Market for Genetic Testing, by Country/Region, 2022–2031 (USD Million)
Table 37 Middle East & Africa Molecular Diagnostics Market for Neurological Diseases, by Country/Region, 2022–2031 (USD Million)
Table 38 Middle East & Africa Molecular Diagnostics Market for Cardiovascular Diseases, by Country/Region, 2022–2031 (USD Million)
Table 39 Middle East & Africa Molecular Diagnostics Market for Other Applications, by Country/Region, 2022–2031 (USD Million)
Table 40 Middle East & Africa Molecular Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 41 Middle East & Africa Molecular Diagnostics Market for Hospitals & Clinics, by Country/Region, 2022–2031 (USD Million)
Table 42 Middle East & Africa Molecular Diagnostics Market for Diagnostic Laboratories, by Country/Region, 2022–2031 (USD Million)
Table 43 Middle East & Africa Molecular Diagnostics Market for Academic & Research Institutes, by Country/Region, 2022–2031 (USD Million)
Table 44 Middle East & Africa Molecular Diagnostics Market for Other End Users, by Country/Region, 2022–2031 (USD Million)
Table 45 Middle East & Africa Molecular Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
Table 46 Saudi Arabia: Molecular Diagnostics Market, by Offering, 2022–2031 (USD Million)
Table 47 Saudi Arabia: Molecular Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 48 Saudi Arabia: Molecular Diagnostics Market, by Technology, 2022–2031 (USD Million)
Table 49 Saudi Arabia: Molecular Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 50 Saudi Arabia: Molecular Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 51 Saudi Arabia: Molecular Diagnostics Market for Oncology, by Type, 2022–2031 (USD Million)
Table 52 Saudi Arabia: Molecular Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 53 UAE: Molecular Diagnostics Market, by Offering, 2022–2031 (USD Million)
Table 54 UAE: Molecular Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 55 UAE: Molecular Diagnostics Market, by Technology, 2022–2031 (USD Million)
Table 56 UAE: Molecular Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 57 UAE: Molecular Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 58 UAE: Molecular Diagnostics Market for Oncology, by Type, 2022–2031 (USD Million)
Table 59 UAE: Molecular Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 60 Oman: Molecular Diagnostics Market, by Offering, 2022–2031 (USD Million)
Table 61 Oman: Molecular Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 62 Oman: Molecular Diagnostics Market, by Technology, 2022–2031 (USD Million)
Table 63 Oman: Molecular Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 64 Oman: Molecular Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 65 Oman: Molecular Diagnostics Market for Oncology, by Type, 2022–2031 (USD Million)
Table 66 Oman: Molecular Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 67 Kuwait: Molecular Diagnostics Market, by Offering, 2022–2031 (USD Million)
Table 68 Kuwait: Molecular Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 69 Kuwait: Molecular Diagnostics Market, by Technology, 2022–2031 (USD Million)
Table 70 Kuwait: Molecular Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 71 Kuwait: Molecular Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 72 Kuwait: Molecular Diagnostics Market for Oncology, by Type, 2022–2031 (USD Million)
Table 73 Kuwait: Molecular Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 74 Egypt: Molecular Diagnostics Market, by Offering, 2022–2031 (USD Million)
Table 75 Egypt: Molecular Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 76 Egypt: Molecular Diagnostics Market, by Technology, 2022–2031 (USD Million)
Table 77 Egypt: Molecular Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 78 Egypt: Molecular Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 79 Egypt: Molecular Diagnostics Market for Oncology, by Type, 2022–2031 (USD Million)
Table 80 Egypt: Molecular Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 81 South Africa: Molecular Diagnostics Market, by Offering, 2022–2031 (USD Million)
Table 82 South Africa: Molecular Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 83 South Africa: Molecular Diagnostics Market, by Technology, 2022–2031 (USD Million)
Table 84 South Africa: Molecular Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 85 South Africa: Molecular Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 86 South Africa: Molecular Diagnostics Market for Oncology, by Type, 2022–2031 (USD Million)
Table 87 South Africa: Molecular Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 88 Rest of Middle East & Africa: Molecular Diagnostics Market, by Offering, 2022–2031 (USD Million)
Table 89 Rest of Middle East & Africa: Molecular Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 90 Rest of Middle East & Africa: Molecular Diagnostics Market, by Technology, 2022–2031 (USD Million)
Table 91 Rest of Middle East & Africa: Molecular Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 92 Rest of Middle East & Africa: Molecular Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 93 Rest of Middle East & Africa: Molecular Diagnostics Market for Oncology, by Type, 2022–2031 (USD Million)
Table 94 Rest of Middle East & Africa: Molecular Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 95 Recent Developments, by Company, 2020–2024
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for the Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Middle East & Africa Molecular Diagnostics Market, by Offering, 2024 Vs. 2031 (USD Million)
Figure 8 Middle East & Africa Molecular Diagnostics Market, by Test Type, 2024 Vs. 2031 (USD Million)
Figure 9 Middle East & Africa Molecular Diagnostics Market, by Technology, 2024 Vs. 2031 (USD Million)
Figure 10 Middle East & Africa Molecular Diagnostics Market, by Application, 2024 Vs. 2031 (USD Million)
Figure 11 Middle East & Africa Molecular Diagnostics Market, by End User, 2024 Vs. 2031 (USD Million)
Figure 12 Middle East & Africa Molecular Diagnostics Market, by Country/Region
Figure 13 Market Dynamics: Middle East & Africa Molecular Diagnostics Market
Figure 14 Middle East & Africa Molecular Diagnostics Market, by Offering, 2024 Vs. 2031 (USD Million)
Figure 15 Middle East & Africa Molecular Diagnostics Market, by Test Type, 2024 Vs. 2031 (USD Million)
Figure 16 Middle East & Africa Molecular Diagnostics Market, by Technology, 2024 Vs. 2031 (USD Million)
Figure 17 Middle East & Africa Molecular Diagnostics Market, by Application, 2024 Vs. 2031 (USD Million)
Figure 18 Middle East & Africa Molecular Diagnostics Market, by End User, 2024 Vs. 2031 (USD Million)
Figure 19 Middle East & Africa Molecular Diagnostics Market, by Country/Region, 2024 Vs. 2031 (USD Million)
Figure 20 Middle East & Africa Molecular Diagnostics Market Snapshot
Figure 21 Key Growth Strategies Adopted by Leading Players (2020–2024)
Figure 22 Middle East & Africa Molecular Diagnostics Market: Competitive Benchmarking, by Type
Figure 23 Middle East & Africa Molecular Diagnostics Market: Competitive Dashboard
Figure 24 Middle East & Africa Molecular Diagnostics Market: Market Share Analysis/ Market Ranking (2023)
Figure 25 F. Hoffmann-La Roche Ltd.: Financial Overview (2022)
Figure 26 Thermo Fisher Scientific, Inc.: Financial Overview (2022)
Figure 27 Becton, Dickinson and Company: Financial Overview (2022)
Figure 28 Illumina, Inc.: Financial Overview (2022)
Figure 29 AstraZeneca Gulf FZ LLC: Financial Overview (2022)
Figure 30 QIAGEN N.V.: Financial Overview (2022)
Figure 31 Danaher Corporation: Financial Overview (2022)
Figure 32 Abbott Laboratories: Financial Overview (2022)
Figure 33 Agilent Technologies, Inc.: Financial Overview (2023)
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Europe Molecular Diagnostics Market - Opportunity Analysis and Industry Forecast (2024 -2030)
Published Date: Jul-2024
North America Molecular Diagnostics Market - Opportunity Analysis And Industry Forecast (2024-2030)
Published Date: Jul-2024
Middle East & Africa NGS Market - Opportunity Analysis And Industry Forecast (2024-2031)
Published Date: Feb-2024
